EGFR and non-small cell lung carcinoma: Whether neoadjuvant TKI therapy is superior to neoadjuvant chemotherapy and whether neoadjuvant TKI therapy, adjuvant TKI therapy, or the combination is more effective in improving the prognosis of patient with resectable EGFR-mutated NSCLC needs to be further validated in future phase 3 clinical trials.